BioLineRX
BLRX
28 hedge funds and large institutions have $4.01M invested in BioLineRX in 2021 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 8 reducing their positions, and 6 closing their positions.
0% more funds holding
Funds holding: 28 → 28 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
0.03% less ownership
Funds ownership: 0.03% → 0.01% (-0.03%)
7% less call options, than puts
Call options by funds: $86K | Put options by funds: $92K
70% less capital invested
Capital invested by funds: $13.5M → $4.01M (-$9.44M)
75% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$893K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$132K |
| 3 |
GWM
Geneos Wealth Management
Englewood,
Colorado
|
+$51.3K |
| 4 |
VF
Virtu Financial
New York
|
+$48.7K |
| 5 |
Millennium Management
New York
|
+$43.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
-$7.65M |
| 2 |
Renaissance Technologies
New York
|
-$1.26M |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$558K |
| 4 |
Morgan Stanley
New York
|
-$504K |
| 5 |
PVH
Psagot Value Holdings
Tel Aviv,
Israel
|
-$326K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CWP
26
Concord Wealth Partners
Abingdon,
Virginia
| $1K | -$2.35K | -20 | -80% |
|
27
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $1K | – | – | – |
|
|
RE
28
RBC Europe
London,
United Kingdom
| $37 | – | – | – |
|
|
SCM
29
Sio Capital Management
New York
| – | -$7.65M | -68,544 | Closed |
|
|
SCM
30
Silverarc Capital Management
Boston,
Massachusetts
| – | -$558K | -5,000 | Closed |
|
|
PVH
31
Psagot Value Holdings
Tel Aviv,
Israel
| – | -$326K | -2,925 | Closed |
|
|
SSA
32
Schonfeld Strategic Advisors
New York
| – | -$213K | -1,913 | Closed |
|
33
Goldman Sachs
New York
| – | -$46K | -416 | Closed |
|
|
RJA
34
Raymond James & Associates
St Petersburg,
Florida
| – | -$35K | -315 | Closed |
|
BLRX Hedge Fund Activity: Q2 2021 in Review
28 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q2 2021, worth a combined $4.01M — down 70% from $13.5M a quarter earlier.
Fund positioning in BLRX was balanced in Q2 2021: 6 funds opened new positions, 6 closed out, 2 added to existing stakes and 8 trimmed.
The largest buyer was Parkman Healthcare Partners, adding an estimated $893K. The largest seller was Sio Capital Management, exiting entirely with an estimated $7.65M sold.
- 28 institutional investors held BioLineRX (BLRX) as of Q2 2021, unchanged from Q1 2021.
- Funds reported $4.01M of BioLineRX stock for Q2 2021, down 70% quarter-over-quarter.
- 6 funds opened new BioLineRX positions in Q2 2021 and 6 closed out, a net change of 0 holders.
- The largest BioLineRX buyer in Q2 2021 was Parkman Healthcare Partners, an estimated $893K added.
- The largest BioLineRX seller in Q2 2021 was Sio Capital Management, an estimated $7.65M sold.
Based on aggregated 13F filings for Q2 2021.